Dr Harry Hixson joins NovaBay
This article was originally published in Scrip
Executive Summary
NovaBay Pharmaceuticals, a US clinical-stage biopharmaceutical company developing non-antibiotic anti-infective products for the treatment or prevention of bacterial, fungal and viral infections, has appointed Dr Harry Hixson to its board of directors. He is chairman of the board at Sequenom and a member of the board at Infinity Pharmaceuticals.